Keywords
Mortality
Trends
Myeloproliferative Neoplasms
Categories
Date
- Submitted: Aug 24, 2025
- Published: Sep 27, 2025
How to Cite
Abstract
Background: Polycythemia vera (PV) is a rare myeloproliferative neoplasm characterized by excessive red blood cell production, leading to increased risk of thrombosis and other complications. Despite its clinical significance, trends in PV mortality across demographic groups in the US remain understudied.
Methods: Nationwide mortality records were obtained from the CDC-WONDER database from 1999 to 2023 among U.S. adults aged ≥45 with PV. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated for variables. Joinpoint regression analysis was utilized to evaluate annual percent changes (APCs).
Results: From 1999 to 2023, a total of 24,236 deaths occurred among adults with PV in the U.S. The overall AAMR decreased from 1.15 in 1999 to 0.73 in 2023 (AAPC: -1.96; 95% CI: -2.28 to -1.73; p < 0.001). The AAMR for men decreased from 1.38 in 1999 to 0.87 in 2023 (AAPC-1.88; 95% CI: -2.36 to -1.37; p < 0.001), and for women decreased from 1 in 1999 to 0.62 in 2023 (AAPC: -2.03; 95% CI: -2.66 to -1.43; p < 0.001). Across racial/ethnic groups, AAMR was highest in non-Hispanic White (0.93 per 100,000). Overall, AAMRs were highest in the Midwest (0.95). The majority of deaths occurred in medical facilities (39.36%). Rural areas had a higher overall AAMR (0.91) compared to urban areas (0.82).
Conclusion: Trends in (PV) mortality declined overall from 1999 to 2023—higher trends observed in men, rural areas, the Midwest region, and NH White.
References
1. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European L. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011: 761 [PMID: 21205761, https://doi.org/10.1200/JCO.2010.31.8436]
2. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. CMAJ. 2020: E913 [PMID: 32778603, https://doi.org/10.1503/cmaj.191587]
3. Mustjoki S, Borze I, Lasho TL, Alitalo R, Pardanani A, Knuutila S, Juvonen E. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV). Leuk Res. 2009: 54 [PMID: 18760472, https://doi.org/10.1016/j.leukres.2008.07.008]
4. Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022: 694 [PMID: 34689695, https://doi.org/10.1080/10428194.2021.1992756]
5. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014: 595 [PMID: 23768070, https://doi.org/10.3109/10428194.2013.813500]
6. Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022: 106809 [PMID: 35220060, https://doi.org/10.1016/j.leukres.2022.106809]
7. Ma JE, Lee JUJ, Sartori-Valinotti JC, Rooke TW, Sandroni P, Davis MDP. Erythromelalgia: A Review of Medical Management Options and Our Approach to Management. Mayo Clin Proc. 2023: 136 [PMID: 36470753, https://doi.org/10.1016/j.mayocp.2022.08.005]
8. Khanal N, Giri S, Upadhyay S, Shostrom VK, Pathak R, Bhatt VR. Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. Leuk Lymphoma. 2016: 129 [PMID: 26159045, https://doi.org/10.3109/10428194.2015.1071492]
9. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022: 1703 [PMID: 35732831, https://doi.org/10.1038/s41375-022-01613-1]
10. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017: 94 [PMID: 27991718, https://doi.org/10.1002/ajh.24607]
11. Saleem MA, Khan M, Lal A, Rath S, Hamed BM, Pakkam M, Aziz N, Nabi W, Bhat A. Analyzing trends and disparities in polycythemia vera mortality in the U.S. from 1999 to 2020. Journal of Clinical Oncology. 2025: https://doi.org/10.1200/JCO.2025.43.16_suppl.e18587]
12. Hemida MF, Ibrahim AA, Mohamed A, Patel K, Qadri M. MPN-1260: Disparities and Trends in Polycythemia Vera Mortality in Elderly Adults From 1999 to 2020. Clinical Lymphoma Myeloma and Leukemia. 2025: https://doi.org/10.1016/s2152-2650(25)02165-2]
13. Hemida MF, Ibrahim AA, Mohamed A, Jairamani S. MPN-1385: Trends and Disparities in Renal Disease-Related Mortality Among Adults With Myeloproliferative Neoplasms in the US. Clinical Lymphoma Myeloma and Leukemia. 2025: S694 https://doi.org/10.1016/s2152-2650(25)02173-1]
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008: 344 [PMID: 18313558, https://doi.org/10.1016/j.jclinepi.2007.11.008]
15. Aggarwal R, Chiu N, Loccoh EC, Kazi DS, Yeh RW, Wadhera RK. Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018. J Am Coll Cardiol. 2021: 1480 [PMID: 33736831, https://doi.org/10.1016/j.jacc.2021.01.032]
16. Ingram DD, Franco SJ. 2013 NCHS Urban-Rural Classification Scheme for Counties. Vital Health Stat 2. 2014: 1 [PMID: 24776070,
17. Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998: 1 [PMID: 9796247,
18. Program SR. Joinpoint Regression Program, Joinpoint Trend Analysis Software [Internet]. 2025.
19. Landolfi R, Di Gennaro L, Nicolazzi MA, Giarretta I, Marfisi R, Marchioli R. Polycythemia vera: gender-related phenotypic differences. Intern Emerg Med. 2012: 509 [PMID: 21660494, https://doi.org/10.1007/s11739-011-0634-3]
20. McNally RJQ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematological Oncology. 1997: 173 https://doi.org/10.1002/(sici)1099-1069(199711)15:4<173::Aid-hon610>3.0.Co;2-k]
21. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002: 1071 [PMID: 12199787, https://doi.org/10.1046/j.1365-2141.2002.03750.x]
22. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol. 2015: 2131 [PMID: 25968903, https://doi.org/10.1007/s00432-015-1983-5]
23. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, Committee EG. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015: v85 [PMID: 26242182, https://doi.org/10.1093/annonc/mdv203]
24. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018: 1057 [PMID: 29515238, https://doi.org/10.1038/s41375-018-0077-1]
25. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, Martinez-Lopez J, Cuevas B, Mata MI, Garcia-Gutierrez V, Aragues P, Montesdeoca S, Burgaleta C, Caballero G, Hernandez-Rivas JA, Duran MA, Gomez-Casares MT, Besses C, Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia N. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016: 786 [PMID: 26898196, https://doi.org/10.1111/bjh.13886]
26. Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia. 2007: 2210 [PMID: 17507997, https://doi.org/10.1038/sj.leu.2404755]
27. Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007: 485 [PMID: 17426257, https://doi.org/10.1182/blood-2007-01-071068]
28. Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010: 1090 [PMID: 20133898, https://doi.org/10.3324/haematol.2009.014407]
29. Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, Williams DM, Rogers O, Gocke CD, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020: 2567 [PMID: 32542392, https://doi.org/10.1182/bloodadvances.2019001407]
30. Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. Thrombosis. 2011: 874146 [PMID: 22084670, https://doi.org/10.1155/2011/874146]
31. Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kroger N. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014: 916 [PMID: 24389309, https://doi.org/10.3324/haematol.2013.094284]
32. Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017: 1590 [PMID: 28085188, https://doi.org/10.1002/cncr.30526]
33. Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017: 1699 [PMID: 28724539, https://doi.org/10.1182/blood-2017-04-778225]
34. Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012: 1520 [PMID: 22771484, https://doi.org/10.1158/1055-9965.EPI-12-0466]
35. Dominick KL, Golightly YM, Bosworth HB. Racial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritis. Ethn Dis. 2005: 116 [PMID: 15720058,
36. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation. 1990: 374 [PMID: 2305467, https://doi.org/10.1097/00007890-199002000-00029]
37. Brady AK, Fu AZ, Earl M, Kalaycio M, Advani A, Saunthararajah Y, Sobecks R, Copelan E, Sekeres MA. Race and intensity of post-remission therapy in acute myeloid leukemia. Leuk Res. 2011: 346 [PMID: 20696474, https://doi.org/10.1016/j.leukres.2010.07.020]
38. Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control. 2016: 327 [PMID: 27842322, https://doi.org/10.1177/107327481602300404]
39. Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016: 2827 [PMID: 27104965, https://doi.org/10.3109/10428194.2016.1170828]
40. Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). J Natl Cancer Inst. 2015: [PMID: 26160883, https://doi.org/10.1093/jnci/djv188]
41. Barker A, Nienstedt L, Kemper L, McBride T, Mueller K. Comparing Rural and Urban Medicare Advantage Beneficiary Characteristics. Rural Policy Brief. 2019: 1 [PMID: 30995707,
42. Hitt WC, Low G, Bird TM, Ott R. Telemedical cervical cancer screening to bridge medicaid service care gap for rural women. Telemed J E Health. 2013: 403 [PMID: 23600410, https://doi.org/10.1089/tmj.2012.0148]
43. Hitt WC, Low GM, Lynch CE, Gauss CH, Magann EF, Lowery CL, Eswaran H. Application of a Telecolposcopy Program in Rural Settings. Telemed J E Health. 2016: 816 [PMID: 27128600, https://doi.org/10.1089/tmj.2015.0260]
44. Mette LA, Saldivar AM, Poullard NE, Torres IC, Seth SG, Pollock BH, Tomlinson GE. Reaching high-risk underserved individuals for cancer genetic counseling by video-teleconferencing. J Community Support Oncol. 2016: 162 [PMID: 27152515, https://doi.org/10.12788/jcso.0247]
45. Ward MM, Ullrich F, Matthews K, Rushton G, Tracy R, Bajorin DF, Goldstein MA, Kosty MP, Bruinooge SS, Hanley A, Lynch CF. Access to chemotherapy services by availability of local and visiting oncologists. J Oncol Pract. 2014: 26 [PMID: 24443731, https://doi.org/10.1200/JOP.2013.001217]
46. Gruca TS, Nam I, Tracy R. Trends in medical oncology outreach clinics in rural areas. J Oncol Pract. 2014: e313 [PMID: 25052498, https://doi.org/10.1200/JOP.2013.001350]
47. Ray MA, Faris NR, Fehnel C, Derrick A, Smeltzer MP, Meadows-Taylor MB, Ariganjoye F, Pacheco A, Optican R, Tonkin K, Wright J, Fox R, Callahan T, Robbins ET, Walsh W, Lammers P, Satpute S, Osarogiagbon RU. Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System. JTO Clin Res Rep. 2021: 100203 [PMID: 34590046, https://doi.org/10.1016/j.jtocrr.2021.100203]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Alyaa Ahmed Ibrahim, Mohamed Fawzi Hemida, MD, Mirna Hussein, Maryam Saghir, Mohammad Rayyan Faisal, FNU Kritika, Krish Patel, Amro Ali, MD, Eshal Saghir, Mahmoud Tablawy, Abdelrhman H. Mohamed, Amr Arafa, MD